Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational
Progress on May 23, 2024
Halle (Saale) / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate
the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ended March 31, 2024 and provide a corporate update on Thursday, May 23, 2024. The Company will host a conference call and webcast open to the public.
Conference call details
Date: May 23, 2024
Time: 3:00 pm CEST / 9:00 am EDT
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon´s website at: https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may pre-register and will
receive dedicated dial-in details to easily and quickly access the call via the
following website:
https://register.vevent.com/register/BI9aadfa99e014435493eca917a11150f1
It is suggested participants dial into the conference call 15 minutes prior to
the scheduled start time to avoid any delays in attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing
innovative small molecule-based medicines. Driven by its passion for ground-
breaking science and innovation, the Company strives to change the lives of
patients in need suffering from severe diseases. The Company leverages its in-
depth expertise in understanding post-translational modifications to develop
medicines that modulate the activity and stability of proteins which are altered
in disease settings. The Company has established a pipeline of orally available
small molecule inhibitors for various indications including Alzheimer's disease,
inflammatory and fibrotic disorders, including of the kidney, and
cancer. www.vivoryon.com (http://www.vivoryon.com/).
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without
limitation, those regarding the business strategy, management plans and
objectives for future operations of Vivoryon Therapeutics N.V. (the "Company"),
estimates and projections with respect to the market for the Company's products
and forecasts and statements as to when the Company's products may be available.
Words such as "anticipate," "believe," "estimate," "expect," "forecast,"
"intend," "may," "plan," "project," "predict," "should" and "will" and similar
expressions as they relate to the Company are intended to identify such forward-
looking statements. These forward-looking statements are not guarantees of
future performance; rather they are based on the Management's current
expectations and assumptions about future events and trends, the economy and
other future conditions. The forward-looking statements involve a number of
known and unknown risks and uncertainties. These risks and uncertainties and
other factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. The Company's results of
operations, cash needs, financial condition, liquidity, prospects, future
transactions, strategies or events may differ materially from those expressed or
implied in such forward-looking statements and from expectations. As a result,
no undue reliance should be placed on such forward-looking statements. This
press release does not contain risk factors. Certain risk factors that may
affect the Company's future financial results are discussed in the published
annual financial statements of the Company. This press release, including any
forward-looking statements, speaks only as of the date of this press release.
The Company does not assume any obligation to update any information or forward-
looking statements contained herein, save for any information required to be
disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com (https://www.globenewswire.com/Tracker?data=b9UrN-
wPmMEgTsB_ta3w0Tny2Xh8EmMfmrCJD5qciAb3pgarsfpEcDaFUwYP9TPGq4QcoTos5gr-
rHMRevqB9Q==)
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu (https://www.globenewswire.com/Tracker?data=vYf-
dM8cK2R5zoaW687_kVbIA-
6l0o2Y9epjuPZYqT5heBkYR_QFk4W4YI_5G59uh8m8Lom_Y1kizUaZZ9ZN-
yAZyxvccw_27nWNotFWj7Y=)
Â